IL129407A0
(en)
|
1996-10-18 |
2000-02-17 |
Vertex Pharma |
Inhibitors of serine proteases particularly hepatitis C virus NS3 protease pharmaceutical compositions containing the same and the use thereof
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
AU3376699A
(en)
*
|
1998-03-31 |
1999-10-18 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
GB9809664D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
CA2376961A1
(en)
*
|
1999-07-26 |
2001-02-01 |
Bristol-Myers Squibb Pharma Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
CN101684146A
(zh)
*
|
1999-11-24 |
2010-03-31 |
诺华疫苗和诊断公司 |
新颖的hcv非结构多肽
|
US6986892B1
(en)
|
1999-11-24 |
2006-01-17 |
Chiron Corporation |
Immunogenic Hepatitis C virus non-structural polypeptides
|
AU2055301A
(en)
*
|
1999-12-03 |
2001-06-12 |
Bristol-Myers Squibb Pharma Company |
Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
|
US6613507B1
(en)
|
2000-03-21 |
2003-09-02 |
Yu-an Chang |
Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
|
PL359359A1
(en)
*
|
2000-04-05 |
2004-08-23 |
Schering Corporation |
Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
|
CZ20023473A3
(cs)
*
|
2000-04-19 |
2003-01-15 |
Schering Corporation |
Makrocyklická sloučenina a farmaceutický prostředek
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
NZ547204A
(en)
|
2000-05-26 |
2008-01-31 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
BR0112666A
(pt)
|
2000-07-21 |
2003-06-10 |
Schering Corp |
Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
|
RU2355700C9
(ru)
|
2000-07-21 |
2010-03-20 |
Шеринг Корпорейшн |
Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
CN1646141B
(zh)
|
2000-10-18 |
2014-06-25 |
吉利德制药有限责任公司 |
用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
MXPA03006514A
(es)
|
2001-01-22 |
2004-12-02 |
Merck & Co Inc |
Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico.
|
US6909000B2
(en)
|
2001-07-11 |
2005-06-21 |
Vertex Pharmaceuticals Incorporated |
Bridged bicyclic serine protease inhibitors
|
AU2002348414B2
(en)
|
2001-10-24 |
2009-10-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
EP1440068A1
(en)
*
|
2001-11-02 |
2004-07-28 |
Glaxo Group Limited |
Acyl dihydro pyrrole derivatives as hcv inhibitors
|
WO2003051910A2
(en)
*
|
2001-12-14 |
2003-06-26 |
Michael Joyce |
Inhibitors of hepatitis c virus protease
|
DE60329367D1
(de)
|
2002-01-23 |
2009-11-05 |
Schering Corp |
Verwendung bei der bekämpfung von hepatitis c virusinfektion
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
JP2005535574A
(ja)
|
2002-04-11 |
2005-11-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、特にhcvns3−ns4aプロテアーゼのインヒビター
|
DE60324552D1
(en)
|
2002-05-20 |
2008-12-18 |
Bristol Myers Squibb Co |
Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
|
DE60336550D1
(de)
|
2002-05-20 |
2011-05-12 |
Bristol Myers Squibb Co |
Inhibitoren des hepatitis-c-virus
|
EP1506000B9
(en)
|
2002-05-20 |
2011-08-31 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
WO2004002999A2
(en)
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
KR20050088079A
(ko)
|
2002-11-15 |
2005-09-01 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
|
CN1791599A
(zh)
*
|
2003-05-21 |
2006-06-21 |
贝林格尔.英格海姆国际有限公司 |
丙型肝炎抑制剂化合物
|
CA2734052A1
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
PL1658302T3
(pl)
|
2003-07-25 |
2011-03-31 |
Idenix Pharmaceuticals Inc |
Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C
|
CN1867579A
(zh)
|
2003-08-26 |
2006-11-22 |
先灵公司 |
丙肝病毒的新的肽模拟物ns3-丝氨酸蛋白酶抑制剂
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
US7642235B2
(en)
|
2003-09-22 |
2010-01-05 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
KR20060085248A
(ko)
|
2003-09-26 |
2006-07-26 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 세린 프로테아제의마크로사이클릭 억제제
|
RU2006115558A
(ru)
|
2003-10-10 |
2007-11-20 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы
|
EP2407470A3
(en)
|
2003-10-14 |
2015-06-10 |
F. Hoffmann-La Roche Ltd. |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
EP1944042A1
(en)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinations for HCV treatment
|
WO2005042570A1
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Hcv ns3-ns4a protease resistance mutants
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MXPA06005683A
(es)
|
2003-11-20 |
2006-12-14 |
Schering Corp |
Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
EP1730167B1
(en)
|
2004-01-21 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Macrocyclic peptides active against the hepatitis c virus
|
ATE461209T1
(de)
|
2004-01-30 |
2010-04-15 |
Medivir Ab |
Hcv ns-3 serine protease inhibitoren
|
EP2311851A3
(en)
|
2004-02-04 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
ES2431314T3
(es)
|
2004-02-20 |
2013-11-26 |
Boehringer Ingelheim International Gmbh |
Inhibidores de polimerasa vírica
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
DK1719773T3
(da)
|
2004-02-24 |
2009-06-29 |
Japan Tobacco Inc |
Kondenserede heterotetracykliske forbindelser og anvendelse deraf som HCV-polymeraseinhibitor
|
TW200529823A
(en)
|
2004-02-27 |
2005-09-16 |
Schering Corp |
Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
MY145081A
(en)
|
2004-02-27 |
2011-12-15 |
Schering Corp |
Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
|
JP2007525510A
(ja)
|
2004-02-27 |
2007-09-06 |
シェーリング コーポレイション |
C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての化合物
|
TW200536528A
(en)
|
2004-02-27 |
2005-11-16 |
Schering Corp |
Novel inhibitors of hepatitis C virus NS3 protease
|
CA2557307A1
(en)
|
2004-02-27 |
2005-09-22 |
Schering Corporation |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
WO2005123087A2
(en)
|
2004-06-15 |
2005-12-29 |
Merck & Co., Inc. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
US20070265222A1
(en)
|
2004-06-24 |
2007-11-15 |
Maccoss Malcolm |
Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
|
CA2573346C
(en)
*
|
2004-07-20 |
2011-09-20 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
UY29016A1
(es)
*
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1797111B1
(en)
|
2004-08-27 |
2011-06-22 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
|
RU2433124C2
(ru)
|
2004-09-14 |
2011-11-10 |
Фармассет, Инк. |
Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
|
EP2374464A3
(en)
|
2004-10-01 |
2011-10-26 |
Vertex Pharmaceuticals Incorporated |
HCV N3S-NS4A protease inhibition
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7879797B2
(en)
|
2005-05-02 |
2011-02-01 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2546246A3
(en)
|
2005-05-13 |
2013-04-24 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2006130686A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors in combination with food
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
AU2006252553B2
(en)
|
2005-06-02 |
2012-03-29 |
Merck Sharp & Dohme Corp. |
Combination of HCV protease inhibitors with a surfactant
|
JP2008546708A
(ja)
|
2005-06-17 |
2008-12-25 |
ノバルティス アクチエンゲゼルシャフト |
Hcvにおけるサングリフェリンの使用
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
BRPI0613962A2
(pt)
|
2005-07-25 |
2009-03-24 |
Intermune Inc |
inibidores macrocìclicos inovadores de replicação de vìrus da hepatite c
|
US7666834B2
(en)
|
2005-07-29 |
2010-02-23 |
Tibotec Pharmaceuticals Ltd. |
Macrocyclic inhibitors of hepatitis C virus
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
AR055105A1
(es)
|
2005-07-29 |
2007-08-08 |
Tibotec Pharm Ltd |
Inhibidores macrociclicos del virus de la hepatitis c
|
AR057704A1
(es)
|
2005-07-29 |
2007-12-12 |
Tibotec Pharm Ltd |
Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto
|
AR054882A1
(es)
|
2005-07-29 |
2007-07-25 |
Tibotec Pharm Ltd |
Inhibidores macrociclicos del virus de la hepatitis c
|
AU2006274862B2
(en)
|
2005-07-29 |
2012-03-22 |
Medivir Ab |
Macrocyclic inhibitors of hepatitis C virus
|
WO2007014925A1
(en)
|
2005-07-29 |
2007-02-08 |
Tibotec Pharmaceuticals Ltd. |
Macrocylic inhibitors of hepatitis c virus
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
WO2007016441A1
(en)
|
2005-08-01 |
2007-02-08 |
Merck & Co., Inc. |
Macrocyclic peptides as hcv ns3 protease inhibitors
|
US20070105781A1
(en)
*
|
2005-08-02 |
2007-05-10 |
Steve Lyons |
Inhibitors of serine proteases
|
US7632821B2
(en)
|
2005-08-09 |
2009-12-15 |
Merck & Co., Inc. |
Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
|
EP1915378A4
(en)
|
2005-08-12 |
2009-07-22 |
Boehringer Ingelheim Int |
VIRUS POLYMERASE INHIBITORS
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
ES2344156T3
(es)
|
2005-08-19 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Procedimientos e intermedios.
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
GEP20104956B
(en)
|
2005-10-11 |
2010-04-12 |
Array Biopharma Inc |
Compounds for inhibiting hepatitis c viral replication and use thereof
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2392589A3
(en)
|
2005-11-11 |
2012-06-20 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
JP2009526070A
(ja)
*
|
2006-02-09 |
2009-07-16 |
シェーリング コーポレイション |
Hcvプロテアーゼ阻害薬とhcvポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法
|
AU2007217355B2
(en)
|
2006-02-27 |
2012-06-21 |
Vertex Pharmaceuticals Incorporated |
Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
|
CA2646229A1
(en)
*
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
WO2007111866A2
(en)
*
|
2006-03-23 |
2007-10-04 |
Schering Corporation |
Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
|
CA2643680A1
(en)
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Hcv/hiv inhibitors and their uses
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
JP2009538327A
(ja)
|
2006-05-23 |
2009-11-05 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
チャネル活性化プロテアーゼ阻害剤である化合物および組成物
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US7935670B2
(en)
|
2006-07-11 |
2011-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
RU2009109355A
(ru)
|
2006-08-17 |
2010-09-27 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Ингибиторы вырусной полимеразы
|
EP2076278B1
(en)
|
2006-10-24 |
2015-05-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic HCV NS3 protease inhibitors
|
EP2079479B1
(en)
|
2006-10-24 |
2014-11-26 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
EP2079480B1
(en)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
CN101568346B
(zh)
|
2006-10-27 |
2015-11-25 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
MX2009004556A
(es)
|
2006-10-27 |
2009-07-10 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del hcv.
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2670260A1
(en)
|
2006-11-15 |
2008-05-22 |
Virochem Pharma Inc. |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2009006056A
(es)
|
2006-12-07 |
2009-06-16 |
Schering Corp |
Formulacion de matriz sensible al ph.
|
CN103224506A
(zh)
|
2006-12-20 |
2013-07-31 |
P.安杰莱蒂分子生物学研究所 |
抗病毒的吲哚
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2081922B1
(en)
|
2006-12-22 |
2012-02-01 |
Schering Corporation |
5,6-Ring annulated indole derivatives and use thereof
|
AU2007339382B2
(en)
|
2006-12-22 |
2013-05-02 |
Merck Sharp & Dohme Llc |
4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
|
KR20090106539A
(ko)
|
2006-12-22 |
2009-10-09 |
쉐링 코포레이션 |
Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
|
CN101641349A
(zh)
|
2007-02-08 |
2010-02-03 |
泰博特克药品有限公司 |
嘧啶取代的大环抑制剂
|
MX2009008518A
(es)
|
2007-02-09 |
2009-08-20 |
Irm Llc |
Compuestos y composiciones como inhibidores de la proteasa activadora de canal.
|
WO2008106058A2
(en)
|
2007-02-27 |
2008-09-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
TW200846343A
(en)
|
2007-02-27 |
2008-12-01 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
PT2144604E
(pt)
|
2007-02-28 |
2011-10-19 |
Conatus Pharmaceuticals Inc |
Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
|
EP2139911A2
(en)
*
|
2007-03-23 |
2010-01-06 |
Schering Corporation |
Hydrazido-peptides as inhibitors of hcv ns3-protease
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008137126A2
(en)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
TW200914013A
(en)
|
2007-06-29 |
2009-04-01 |
Gilead Sciences Inc |
Antiviral compounds
|
AP2874A
(en)
|
2007-06-29 |
2014-03-31 |
Gilead Sciences Inc |
Antiviral compounds
|
AU2008277440A1
(en)
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
US8242140B2
(en)
|
2007-08-03 |
2012-08-14 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
MX2010002317A
(es)
|
2007-08-29 |
2010-03-22 |
Schering Corp |
Derivados de indol sustituidos y metodos para su utilizacion.
|
AU2008295476B2
(en)
|
2007-08-29 |
2013-08-01 |
Merck Sharp & Dohme Corp. |
2, 3-Substituted Indole Derivatives for treating viral infections
|
EP2195317B1
(en)
|
2007-08-29 |
2012-01-18 |
Schering Corporation |
2,3-substituted azaindole derivatives for treating viral infections
|
ATE530546T1
(de)
|
2007-08-30 |
2011-11-15 |
Vertex Pharma |
Kokristalle und pharmazeutische zusammensetzungen damit
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
WO2009064852A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
CN102099351A
(zh)
|
2007-11-16 |
2011-06-15 |
先灵公司 |
3-杂环取代的吲哚衍生物及其使用方法
|
CA2708150A1
(en)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide hcv serine protease inhibitors
|
JP5623289B2
(ja)
|
2007-12-19 |
2014-11-12 |
ベーリンガーインゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ウイルスポリメラーゼインヒビター
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
MX2010008523A
(es)
|
2008-02-04 |
2010-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa.
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8461107B2
(en)
|
2008-04-28 |
2013-06-11 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(en)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
JP5580814B2
(ja)
|
2008-06-13 |
2014-08-27 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3環式インドール誘導体およびその使用方法
|
BRPI0913677A2
(pt)
|
2008-07-02 |
2015-12-15 |
Idenix Pharmaceuticals Inc |
composto, metabólito purificado, método para tratar um hospedeiro infectado com um vírus flaviviridade, composição farmacêutica, método para preparar o composto purificado, e, processo para preparar o composto
|
SI2310095T1
(sl)
|
2008-07-22 |
2013-01-31 |
Merck Sharp & Dohme Corp. |
Makrocikliäśne kuinoksalinske spojine kot hcv ns3 proteazni inhibitorji
|
TW201020245A
(en)
|
2008-08-20 |
2010-06-01 |
Schering Corp |
Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282567B2
(en)
|
2008-08-20 |
2014-10-02 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
AU2009282574B2
(en)
|
2008-08-20 |
2014-08-21 |
Merck Sharp & Dohme Corp. |
Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8470834B2
(en)
|
2008-08-20 |
2013-06-25 |
Merck Sharp & Dohme Corp. |
AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP3025727A1
(en)
|
2008-10-02 |
2016-06-01 |
The J. David Gladstone Institutes |
Methods of treating liver disease
|
AU2009322393B2
(en)
|
2008-12-03 |
2017-02-02 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
BRPI0922364A2
(pt)
|
2008-12-03 |
2017-08-29 |
Presidio Pharmaceuticals Inc |
Composto, composição farmacêutica e uso de um composto
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
EA201100851A1
(ru)
|
2008-12-23 |
2012-04-30 |
Фармассет, Инк. |
Аналоги нуклеозидов
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
AU2010203656A1
(en)
|
2009-01-07 |
2011-07-21 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of HCV and HIV infection
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
EP2410843A4
(en)
|
2009-03-27 |
2012-08-08 |
Presidio Pharmaceuticals Inc |
FUSIONED CORE INHIBITORS OF HEPATITIS C
|
WO2010118078A1
(en)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
CA2761650C
(en)
|
2009-05-13 |
2015-05-26 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic compounds as hepatitis c virus inhibitors
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
AU2010253791A1
(en)
|
2009-05-29 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
|
EP2459582B1
(en)
|
2009-07-30 |
2015-05-27 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
WO2011017389A1
(en)
|
2009-08-05 |
2011-02-10 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
|
DK2477980T3
(en)
|
2009-09-15 |
2016-09-12 |
Taigen Biotechnology Co Ltd |
HCV protease inhibitors
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
WO2011068715A1
(en)
|
2009-11-25 |
2011-06-09 |
Vertex Pharmaceuticals Incorporated |
5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
|
AU2010324871A1
(en)
|
2009-11-25 |
2012-06-14 |
Merck Sharp & Dohme Corp. |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
AU2010341537A1
(en)
|
2009-12-22 |
2012-08-09 |
Merck Sharp & Dohme Corp. |
Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
|
KR20120130173A
(ko)
|
2009-12-24 |
2012-11-29 |
버텍스 파마슈티칼스 인코포레이티드 |
플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
|
US8653025B2
(en)
|
2010-01-27 |
2014-02-18 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
US9433621B2
(en)
|
2010-02-18 |
2016-09-06 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
SG183526A1
(en)
|
2010-03-09 |
2012-09-27 |
Merck Sharp & Dohme |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
WO2011119860A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
AU2011232348A1
(en)
|
2010-03-24 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of Flavivirus infections
|
TW201139438A
(en)
|
2010-03-24 |
2011-11-16 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
CA2794145A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
BR112012024884A2
(pt)
|
2010-03-31 |
2016-10-18 |
Gilead Pharmasset Llc |
síntese estereosseletiva de ativos contendo fósforo
|
MX2012011222A
(es)
|
2010-04-01 |
2013-01-18 |
Centre Nat Rech Scient |
Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
|
EP2575866A4
(en)
|
2010-05-24 |
2013-10-16 |
Presidio Pharmaceuticals Inc |
HCV NS5A INHIBITORS
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
WO2011159826A2
(en)
|
2010-06-15 |
2011-12-22 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
EP2585448A1
(en)
|
2010-06-28 |
2013-05-01 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
UY33473A
(es)
|
2010-06-28 |
2012-01-31 |
Vertex Pharma |
Compuestos y métodos para el tratamiento o la prevencion de infecciones por flavivirus
|
JP2013541499A
(ja)
|
2010-07-26 |
2013-11-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
|
WO2012020036A1
(en)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Hepatitis c virus inhibitors
|
WO2012024363A2
(en)
|
2010-08-17 |
2012-02-23 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flaviviridae viral infections
|
KR101990279B1
(ko)
|
2010-09-21 |
2019-06-19 |
이난타 파마슈티칼스, 인코포레이티드 |
매크로사이클릭 프롤린 유도된 hcv 세린 프로테아제 억제제
|
AU2011314168A1
(en)
|
2010-09-29 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
US9011833B2
(en)
|
2010-10-08 |
2015-04-21 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012123298A1
(en)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2012269643A1
(en)
|
2011-06-16 |
2014-02-06 |
AB Pharma Ltd. |
Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof
|
RU2014102102A
(ru)
|
2011-06-23 |
2015-07-27 |
Дигна Байотек, С.Л. |
КОМПОЗИЦИЯ И КОМБИНИРОВАННЫЙ ПРЕПАРАТ ИНТЕРФЕРОНА-а5 С ИНТЕРФЕРОНОМ-а2 И СПОСОБ ЛЕЧЕНИЯ ХРОНИЧЕСКОГО ГЕПАТИТА С
|
WO2012175581A1
(en)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
TW201317223A
(zh)
|
2011-07-26 |
2013-05-01 |
Vertex Pharma |
噻吩化合物
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
WO2013033899A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033900A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
|
WO2013033901A1
(en)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
AU2012308900A1
(en)
|
2011-09-12 |
2013-05-09 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2755981A4
(en)
|
2011-09-14 |
2015-03-25 |
Merck Sharp & Dohme |
HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
|
CA2847083A1
(en)
|
2011-10-10 |
2013-04-18 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
US9089574B2
(en)
|
2011-11-30 |
2015-07-28 |
Emory University |
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
|
SG11201402899TA
(en)
|
2011-12-06 |
2014-07-30 |
Univ Leland Stanford Junior |
Methods and compositions for treating viral diseases
|
RU2014127848A
(ru)
|
2011-12-16 |
2016-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Ингибиторы hcv ns5a
|
ES2636448T3
(es)
|
2011-12-20 |
2017-10-05 |
Riboscience Llc |
Derivados de nucleósido 2',4'-difluoro-2'-metil sustituidos como inhibidores de la replicación del ARN del VHC
|
US9708357B2
(en)
|
2011-12-20 |
2017-07-18 |
Riboscience, LLC |
4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
US20130217644A1
(en)
|
2012-02-13 |
2013-08-22 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
|
WO2013124335A1
(en)
|
2012-02-24 |
2013-08-29 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2013142157A1
(en)
|
2012-03-22 |
2013-09-26 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
AP3913A
(en)
|
2012-05-22 |
2016-11-26 |
Idenix Pharamaceuticals Inc |
D-amino acid compounds for liver disease
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
PE20151318A1
(es)
|
2012-10-08 |
2015-10-03 |
Idenix Pharmaceuticals Inc |
Analogos de 2'-cloro nucleosido para infeccion por vhc
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
RS55592B1
(sr)
|
2012-10-19 |
2017-06-30 |
Bristol Myers Squibb Co |
9-metil supstituisani heksadekahidrociklopropa(e)pirolo(1,2-a)(1,4)diazaciklopentadecinil karbamat derivati kao nestrukturalni 3 (ns3) proteazni inhibitori za lečenje infekcijavirusom hepatitisa c
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
WO2014070964A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014071007A1
(en)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014078436A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
EP2948440B1
(en)
|
2013-01-23 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Antiviral triazole derivatives
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
TW201526899A
(zh)
|
2013-02-28 |
2015-07-16 |
Alios Biopharma Inc |
醫藥組成物
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
CA2900319A1
(en)
|
2013-03-05 |
2014-09-12 |
F. Hoffmann-La Roche Ag |
Antiviral compounds
|
WO2014137869A1
(en)
|
2013-03-07 |
2014-09-12 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
WO2014186637A1
(en)
|
2013-05-16 |
2014-11-20 |
Riboscience Llc |
4'-fluor0-2'-methyl substituted nucleoside derivatives
|
PE20160119A1
(es)
|
2013-05-16 |
2016-02-24 |
Riboscience Llc |
Derivados de nucleosido 4'-azido, 3'-desoxi-3'-fluoro sustituido
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
ES2792503T3
(es)
|
2013-08-27 |
2020-11-11 |
Gilead Pharmasset Llc |
Formulación combinada de dos compuestos antivirales
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015065817A1
(en)
|
2013-10-30 |
2015-05-07 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
US10449210B2
(en)
|
2014-02-13 |
2019-10-22 |
Ligand Pharmaceuticals Inc. |
Prodrug compounds and their uses
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
CN106687118A
(zh)
|
2014-07-02 |
2017-05-17 |
配体药物公司 |
前药化合物及其用途
|
CN108699106B
(zh)
|
2016-03-04 |
2021-11-30 |
豪夫迈·罗氏有限公司 |
作为htra1抑制剂的新型三氟甲基丙酰胺衍生物
|
EP3423467B1
(en)
|
2016-03-04 |
2021-04-28 |
F. Hoffmann-La Roche AG |
New difluoroketamide derivatives as htra1 inhibitors
|
DK3472149T3
(da)
|
2016-06-21 |
2023-11-27 |
Orion Ophthalmology LLC |
Heterocykliske prolinamidderivater
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
CN109415330A
(zh)
|
2016-07-18 |
2019-03-01 |
豪夫迈·罗氏有限公司 |
作为htra1抑制剂的新型二氟酮酰胺衍生物
|
CN109661389A
(zh)
|
2016-08-23 |
2019-04-19 |
豪夫迈·罗氏有限公司 |
作为htra1抑制剂的新型二氟酮酰胺衍生物
|
JP2019526564A
(ja)
*
|
2016-08-23 |
2019-09-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Htra1阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体
|
JP7299897B2
(ja)
|
2017-09-21 |
2023-06-28 |
リボサイエンス リミティド ライアビリティ カンパニー |
Hcvのrna複製阻害剤としての4’-フルオロ-2’-メチル置換ヌクレオシド誘導体
|
US11970482B2
(en)
|
2018-01-09 |
2024-04-30 |
Ligand Pharmaceuticals Inc. |
Acetal compounds and therapeutic uses thereof
|
KR20210098504A
(ko)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|